ARAY Stock Risk & Deep Value Analysis
Accuray Inc
DVR Score
out of 10
What You Need to Know About ARAY Stock
We analyzed Accuray Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran ARAY through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
How Risky Is ARAY Stock?
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Medium
Competitive Risk
High
Execution Risk
High
Regulatory Risk
Medium
What Are the Red Flags for ARAY?
- ⚠
Further operational losses and accelerated cash burn
- ⚠
Inability to secure new financing, leading to liquidity crisis
- ⚠
Increased competitive pressure or new product launches from rivals
- ⚠
Further shareholder dilution through equity raises
- ⚠
Potential delisting from major exchange due to low share price/market cap
Unlock ARAY Red Flags & Risk Warnings
Create a free account to see the full analysis
Is ARAY Stock Undervalued?
Unlock the full AI analysis for ARAY
Get the complete DVR score, risk analysis, and more
Does ARAY Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Eroding
Moat Sources
2 Identified
The moat is under significant pressure due to financial distress limiting R&D, intense competition from larger, better-funded rivals, and an inability to aggressively expand market share.
Moat Erosion Risks
- •Competitors' superior R&D and product innovation
- •Inability to fund necessary product development and upgrades
- •Loss of customer confidence due to financial instability
ARAY Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive ARAY Stock Higher?
Near-Term (0-6 months)
- •Q3 FY2026 Earnings Report (estimated late May / early June 2026)
- •Any unexpected strategic partnership or distribution agreement
- •Cost-cutting initiatives or operational efficiency improvements
Medium-Term (6-18 months)
- •Successful new financing round (equity or debt, likely dilutive)
- •Major new contract wins for CyberKnife or Radixact systems
- •Positive regulatory updates for pipeline products or geographical expansion
Long-Term (18+ months)
- •Strategic acquisition by a larger medical device company for its IP
- •Successful turnaround leading to sustained positive free cash flow
- •Broad industry shift favoring precise, non-invasive radiation therapies
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for ARAY?
- ✓
Significant cash infusion or strategic investment from a reputable partner
- ✓
Acceleration in order bookings and revenue growth
- ✓
Meaningful improvement in gross margins and reduction in operational cash burn
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for ARAY (Accuray Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
